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Molecular Cardiology
Immunotherapy With Tolerogenic Apolipoprotein
B-100–Loaded Dendritic Cells Attenuates Atherosclerosis in
Hypercholesterolemic Mice
Andreas Hermansson, PhD; Daniel K. Johansson, MSc; Daniel F.J. Ketelhuth, PhD;
John Andersson, PhD; Xinghua Zhou, MD, PhD*; Go¨ran K. Hansson, MD, PhD*
Background—Atherosclerosis is a chronic inflammatory disease characterized by a massive intimal accumulation of
low-density lipoprotein that triggers chronic vascular inflammation with an autoimmune response to low-density
lipoprotein components.
Methods and Results—To dampen the inflammatory component of atherosclerosis, we injected hypercholesterolemic
huB100tgLdlr/ mice (mice transgenic for human apolipoprotein B100 [ApoB100] and deficient for the low-density
lipoprotein receptor) intravenously with dendritic cells (DCs) that had been pulsed with the low-density lipoprotein
protein ApoB100 in combination with the immunosuppressive cytokine interleukin-10. DCs treated with ApoB100 and
interleukin-10 reduced proliferation of effector T cells, inhibited production of interferon-, and increased de novo
generation of regulatory T cells in vitro. Spleen cells from mice treated with DCs plus ApoB100 plus interleukin-10
showed diminished proliferative responses to ApoB100 and significantly dampened T-helper 1 and 2 immunity to
ApoB100. Spleen CD4 T cells from these mice suppressed activation of ApoB100-reactive T cells in a manner
characteristic of regulatory T cells, and mRNA analysis of lymphoid organs showed induction of transcripts
characteristic of these cells. Treatment of huB100tgLdlr/ mice with ApoB100-pulsed tolerogenic DCs led to a
significant (70%) reduction of atherosclerotic lesions in the aorta, with decreased CD4 T-cell infiltration and signs of
reduced systemic inflammation.
Conclusions—Tolerogenic DCs pulsed with ApoB100 reduced the autoimmune response against low-density lipoprotein
and may represent a novel possibility for treatment or prevention of atherosclerosis. (Circulation. 2011;123:1083-
1091.)
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In atherosclerosis, low-density lipoprotein (LDL) accumu-lates within the arterial wall, attracting immune cells and
leading to chronic inflammation.1 This process involves an
autoimmune response to the protein moiety of LDL, apoli-
poprotein B100 (ApoB100).2–5 Antigen-presenting dendritic
cells (DCs) traverse the arterial wall and the atherosclerotic
plaque, where they may take up LDL components before
migrating to lymphoid organs. This could initiate and boost
cellular immune responses by presenting ApoB100 to T cells
in the draining lymph nodes.6–10 Such responses contribute
significantly to the progression of atherosclerosis.11–13
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The evolving plaque is dominated by a T-helper 1 (Th1)–
type response, with production of proinflammatory cytokines
such as interferon- (IFN-), tumor necrosis factor (TNF-),
and interleukin (IL)-12,14 but also chemokines such as CCL2,
CCL5, and CXCL4,15 which stimulate the influx of various
types of leukocytes.16,17 Several therapeutic strategies have
been devised to dampen the inflammatory process in the
plaque, but the limited mechanistic understanding of molec-
ular mechanisms has hampered their translation into clinical
utility.2 However, advances in understanding the plasticity of
the DC system may open up novel possibilities for the
treatment of atherosclerosis.
DCs orchestrate the defense against infectious agents, as
well as the maintenance and regulation of peripheral toler-
ance.18,19 Although immunogenic myeloid DCs play a major
role in the initiation of inflammation and regulation of
adaptive immunity, the tolerogenic properties of such DCs
can be manipulated by immunomodulatory mediators such as
cytokines, which provides opportunities for prevention and
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therapy of autoimmune diseases.20,21 Numerous approaches
have been adopted during recent years to generate tolerogenic
DCs for treatment of autoimmune disorders and improvement
of allograft survival.21 One of the most promising strategies
includes induction of antigen-specific tolerogenic DCs by
incubation with the immunosuppressive cytokine IL-10.
Treatment of DCs with IL-10 downregulates secretion of
inflammatory cytokines such as TNF-, IL-6, and IL-12;
induces anergy of antigen-specific T cells; and promotes
generation of regulatory T cells (Treg).21–27 The utility of
these immunoregulatory DCs as treatment of atherosclerotic
disease has not been examined previously.
Here, we show that IL-10 imposes a regulatory phenotype
on DCs, and that such tolerogenic DCs induce T-cell toler-
ance to ApoB100, blunt Th1 responses, and suppress auto-
immune inflammation in hypercholesterolemic mice in an
ApoB100-specific manner. Treatment of disease-prone hy-
percholesterolemic mice with a single injection of tolerogenic
DCs led to significantly reduced atherosclerosis.
Methods
For an expanded Methods section, please refer to the online-only
Data Supplement.
Preparation of ApoB100
LDL was isolated by ultracentrifugation from pooled plasma of
healthy donors, as described previously,28 and kept in a native state.
ApoB100 was isolated by previously described methods.5,29,30
ApoB100 preparations were more than 90% pure, as evaluated by
gel-filtration high-performance liquid chromatography (GE Health-
care, Uppsala, Sweden).
Isolation and Loading of DCs
Myeloid DCs were generated as described previously.31,32 Briefly,
bone marrow was isolated from huB100tgLdlr/ mice (mice
transgenic for human ApoB100 crossed with mice that were deficient
for the LDL receptor). Bone marrow cells were depleted of red blood
cells and cultured for 8 days in tissue culture dishes at 37°C and
7.5% CO2. DMEM culture medium was supplemented with 10%
FCS, penicillin 50 U/mL, streptomycin 50 g/mL, L-glutamine
2 mmol/L, sodium pyruvate 1 mmol/L, granulocyte-macrophage
colony-stimulating factor 10 ng/mL (Peprotech, Rocky Hill, NJ), and
IL-4 10 ng/mL (Peprotech). Purification of DCs from the differen-
tiated bone marrow cells was performed with a CD11c magnetic
cell-sorting kit (Miltenyi Biotech, Go¨teborg, Sweden) according to
the manufacturer’s instructions.
For cell-transfer experiments, the purified DCs were incubated in
tissue culture dishes with IL-10 (30 ng/mL), with or without
ApoB100 (100 g/mL), in serum-free DMEM containing 1:100 BD
ITS Premix (BD Biosciences, Franklin Lakes, NJ), BSA 1 mg/mL
(Sigma-Aldrich, St Louis, MO), HEPES 10 mmol/L (Gibco Invitro-
gen, Carlsbad, CA), sodium pyruvate 1 mmol/L (Gibco Invitrogen),
nonessential amino acids 1 mmol/L (Sigma-Aldrich), and gentamicin
sulfate 50 g/mL (Sigma-Aldrich) at 37°C in a humid 5% CO2
atmosphere. Four hours later, lipopolysaccharide (0.1 ng/mL; titrated
to start DC maturation) was added. After another 14 hours, the cells
were washed in DMEM, kept on ice, and injected into recipients
within 1 hour. For measurement of cytokine release into the
supernatant, the purified DCs were pulsed in 96-well plates (4105
cells per well).
Animal Experiments and Evaluation of Disease
Eleven-week-old male huB100tgLdlr/ mice (C57BL/6129-
ApoBtm2SgyLdlrtm1Her mice,33,34 kindly provided by Dr Jan Bore´n,
Go¨teborg University), were injected intravenously with 2.5105
DCs pulsed with antigen and/or cytokine. The mice were fed a
high-fat diet (0.15% cholesterol R638, Lantma¨nnen, Malmö, Swe-
den) for 10 weeks starting 5 days after cell therapy. In some
experiments, the mice were also immunized subcutaneously with
100 g of ApoB100 emulsified with complete Freund’s adjuvant 1
week after DC injection. All experiments were approved by the local
ethics committee.
Mice were euthanized under CO2 anesthesia, blood was collected
by cardiac puncture, and the vasculature was perfused with sterile
RNase-free PBS. The descending thoracic aorta was dissected and
fixed in 4% formaldehyde, opened longitudinally, pinned onto black
wax plates, and stained with Sudan IV (Merck AG, Darmstadt,
Germany). Lesion area and total aortic area were calculated with
ImageJ software (National Institutes of Health, Bethesda, MD). Part
of the spleen was used for cell experiments and snap-frozen for RNA
isolation. Inguinal lymph nodes and abdominal aortas were snap-
frozen and used for RNA isolation. Immunohistochemistry was
performed on acetone-fixed cryosections from the aortic root of
dissected mouse hearts as described previously.35
In Vitro Cell Culture Assay
Splenocytes from treated mice were isolated and resuspended in
96-well plates. A total of 5105 splenocytes were incubated with or
without ApoB100 antigen in 200 L of DMEM supplemented with
2.5% mouse serum, penicillin 50 U/mL, streptomycin 50 g/mL,
L-glutamine 2 mmol/L, and sodium pyruvate 1 mmol/L for 72 hours
at 37°C in a humid 5% CO2 atmosphere. One Ci of 3H-thymidine
(Sigma-Aldrich) was added after 60 hours, and DNA replication was
measured with a scintillation counter (Wallac, Turku, Finland).
Cytokines secreted in the cell culture supernatants after 72 hours
were measured with an enzyme-linked immunosorbent assay kit
(Mabtech, Nacka Strand, Sweden) or with a cytometric bead array
flex set kit (BD Biosciences).
Flow Cytometry and Intracellular
Cytokine Staining
To measure surface-marker expression, single-cell suspensions were
prepared and stained with primary labeled antibodies (BD Biosci-
ences) according to the manufacturer’s instructions. For further
characterization of cytokine profiles, 1104 CD4 T cells were
incubated for 96 hours with 4104 DCs treated with or without
IL-10 in the presence of anti-CD3 (2 g/mL) and restimulated for the
last 4 hours of culture at 37°C in 7.5% CO2 with phorbol 12-myris-
tate 13-acetate (50 ng/mL), ionomycin (1 g/mL; Sigma), and
GolgiPlug (1 L per 1 mL; BD Biosciences). All cells were
incubated with FcR block (BD Biosciences) followed by surface
staining for CD4 and intracellular staining for IFN-, IL-10 (BD
Biosciences), or FoxP3 (forkhead box P3; eBioscience, San Diego,
CA) according to the manufacturer’s instructions. In some experi-
ments, cell proliferation was measured by staining with carboxyfluo-
rescein succinimidyl ester (Invitrogen).
Plasma Analyses
The titers of specific antibodies to ApoB100 were measured by
enzyme-linked immunosorbent assay as described previously.5
Plasma cholesterol and triglycerides were measured with enzymatic
colorimetric kits (Randox Laboratory Ltd, Crumlin, United King-
dom) according to the manufacturer’s protocol.
Statistical Analysis
Values are expressed as meanSEM unless otherwise indicated. The
nonparametric Mann-Whitney U test was used for pairwise compar-
isons and the Kruskal-Wallis test for multiple comparisons. Differ-
ences between groups were considered significant at P0.05.
Results
Tolerogenic DCs Promote Regulatory T Cells and
Have an Impaired Ability to Induce Effector
T-Cell Responses
DCs were prepared from bone marrow of huB100tgLdlr/
mice and maturated by lipopolysaccharide treatment in the
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presence or absence of IL-10. These DCs displayed a char-
acteristic CD11cFlt3 I-Ab–positive phenotype with 90%
CD11c cells (online-only Data Supplement Figure I). IL-10
treatment of DCs did not affect the mean cell-surface expres-
sion of the costimulatory factors CD80 and CD86 or the
coinhibitory molecules programmed death ligand 1 (PD-L1)
and programmed death ligand 2 (PD-L2; online-only Data
Supplement Figure I). Secretion of TNF-, monocyte che-
motactic protein-1, and IL-12 from DCs was increased
markedly after uptake of ApoB100 but was repressed signif-
icantly on concomitant treatment with IL-10 (Figure 1).
To assess the functional activity of IL-10–treated DCs, we
added such cells to polyclonally activated spleen CD4 T
cells. This led to significantly reduced IFN- production and
to modestly increased IL-10 production by these T cells
(Figure 2A). The T cells constitutively expressed the costimu-
latory factor CD28 and low levels of CTLA-4 (cytotoxic
T-lymphocyte antigen 4) and ICOS (inducible T-cell co-
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Figure 1. Tolerogenic dendritic cells (DCs) have an impaired capability to induce T-cell effector responses in vitro. DCs were differenti-
ated from mouse bone marrow in the presence of granulocyte-macrophage colony-stimulating factor and interleukin-4. CD11c DCs
were purified by magnetic cell sorting and matured with lipopolysaccharide. To test the DCs for their capability to induce proinflamma-
tory cytokines in the presence of antigen or antiinflammatory cytokine, 2105 cells were seeded in 96-well plates and incubated
together with or without apolipoprotein B100 (ApoB100) in the presence or absence of interleukin-10 (IL-10) for 24 hours, as indicated
by () or () in the graphs. Bar graphs show secretion to culture media of A) TNF- (tumor necrosis factor-) B) IL-12 (interleukin-12)
and C) MCP-1 (monocyte chemotactic protein-1). ***P0.001 vs DCApoB100 (n6 for each experimental group).
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Figure 2. Interleukin-10 (IL-10)–treated dendritic cells (DCs) inhibit T-cell proliferation and effector function but stimulate de novo gener-
ation of regulatory T cells (Treg). A total of 1104 CD11c DCs treated with or without IL-10 were coincubated for 96 hours with 4104
CD4 T cells purified from mouse spleen and activated with anti-CD3. A–C, Fluorescent-activated cell sorter data from a representative
experiment that was performed twice with similar results. A, Intracellular staining of CD4 T cells after 96 hours of coincubation. Cells
were restimulated with phorbol 12-myristate 13-acetate and ionomycin and added together with brefeldin A for the last 5 hours of cul-
ture. CD4 T cells were then stained with anti-interferon (IFN)- and anti-IL-10 according to the manufacturer’s protocol (BD Biosci-
ences). B, Spleen CD4 T cells were depleted of CD25 natural Treg, stained with carboxyfluorescein succinimidyl ester (CFSE) to
visualize cell proliferation, cocultured for 96 hours, and stained for FoxP3. Dot plots show CFSE staining reflecting the number of DNA
replications on the x axis and staining for FoxP3, identifying FoxP3 Treg (top) and FoxP3 effector T cells (bottom), on the y axis. C,
Overlay histogram showing CFSE staining in FoxP3 effector T cells cultured with DCs (shaded area) and DCs pretreated with IL-10
(black line), with peaks reflecting cell divisions (due to dilution of CFSE dye in each cell division, highly proliferating cells are toward the
left and nonproliferating cells are toward the right). Max indicates maximum. D, 5104 cells of the T-cell hybridoma 48.5, which specifi-
cally recognizes apolipoprotein B100 (ApoB100), were coincubated with 2105 washed DCs that had been pretreated for 24 hours in
the presence or absence of IL-10 and ApoB100, as indicated by () or () in the graph. The DCs originated from donor mice express-
ing either I-Ab or I-Ad. T-cell activation was measured 24 hours later by interleukin-2 (IL-2) secretion. **P0.01 vs DCApoB100 (n4);
ns indicates not significant.
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stimulator). The coinhibitory receptor PD-1, which is in-
volved in T-cell inhibition, autoimmunity, and peripheral
tolerance,36 was slightly upregulated on T cells stimulated by
IL-10–treated DCs (online-only Data Supplement Figure II).
Compared with nontreated DCs, exposure to IL-10–treated
DCs more than doubled the number of FoxP3CD4 Treg
cells among purified spleen CD4 T cells that had been
depleted of preexisting CD25 Treg, which suggests de novo
generation (Figure 2B; online-only Data Supplement Table I).
IL-10–treated DCs promoted significantly less effector T-cell
proliferation on polyclonal stimulation than did regular my-
eloid DCs (Figures 2B and 2C; online-only Data Supplement
Table II).
We have found recently that atherogenic T cells recognize
ApoB100-derived peptides of native LDL in an I-Ab–re-
stricted manner.5 When DCs pulsed with ApoB100 and IL-10
were incubated with the ApoB100-specific T-cell hybridoma
48.5, they suppressed its activation compared with its re-
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Figure 3. Tolerogenic dendritic cells (DCs) reduce atherosclerotic lesion formation in the thoracic aorta of huB100tgLdlr/ mice. A,
Mice received 1 intravenous injection with DCs loaded with or without apolipoprotein B100 (ApoB100) and/or interleukin-10 (IL-10) and
were fed a Western diet for 10 weeks. Dissected aortas were stained with Sudan IV, and percent lesion area of total vessel area was cal-
culated with ImageJ image analysis software. B through F, En face photographs of aortas from treatment groups: B, DCs without antigen; C,
DCApoB100; D, DCApoB100IL-10; E, DCIL-10; and F, no DCs. **P0.01 vs all other groups (n7 to 9 mice per group).
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Figure 4. Tolerogenic dendritic cells (DCs)
decrease infiltration of CD4 T cells in aor-
tic root lesions of huB100tgLdlr/ mice
and stabilize lesions. Mice received 1 intra-
venous injection with DCs loaded with or
without apolipoprotein B100 (ApoB100)
and/or interleukin-10 (IL-10) and were fed
a Western diet for 10 weeks. A, Number of
CD4 cells per square millimeter of lesion
area. B, Percent of Sirius red–stained area
in the aortic root of treated groups. C
through F, CD4 immunostaining of repre-
sentative cryosections from the aortic root.
Immunoperoxidase labeling; original mag-
nification 100. G through J, Sirius red
staining of representative cryosections
from the aortic root; original magnification
100. C and G, No antigen; D and H,
DCApoB100; E and I, DCApoB100IL-
10; and F and J, DCIL-10. *P0.05 (n5
to 7 mice per group).
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sponse to DCs pulsed with ApoB100 in the absence of IL-10
(Figure 2D). When DCs from I-Ad donors were used, or when
antibodies against I-Ab were added to the culture, the re-
sponse was abrogated, which demonstrates that I-Ab re-
stricted antigen presentation of ApoB100 by DCs to T cells
(Figure 2D; online-only Data Supplement Figure III). Taken
together, these data show that IL-10 treatment renders DCs
tolerogenic, which leads to reduced T-cell activation in
response to disease-specific antigen and polyclonal stimuli,
increased induction of FoxP3 Treg, and reduced proinflam-
matory effector T-cell responses.
Tolerogenic DCs Presenting ApoB100 Reduce
Atherosclerosis in Hypercholesterolemic Mice
HuB100tgLdlr/ mice were used to test the effect of tolero-
genic DCs on atherosclerosis. These mice express full-length
human ApoB100 in the liver and display humanized hyperlip-
idemic lipoprotein profiles. The huB100tgLdlr/ model per-
mits the use of human ApoB100 as antigen.5 Mice received a
single intravenous injection of DCs that had been pulsed with
either (1) medium, (2) ApoB100 alone (ie, antigen-loaded
myeloid DCs), (3) ApoB100 plus IL-10 (antigen-loaded tolero-
genic DCs), or (4) IL-10 alone (unloaded tolerogenic DCs).
Finally, a fifth group of mice remained untreated. A significant
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Figure 5. Tolerogenic dendritic cells (DCs) generate antigen-specific suppressor regulatory T cells (Treg) and downregulate antigen-specific T
helper responses and inflammation in vivo. A, DCs pulsed with or without apolipoprotein B100 (ApoB100) and interleukin-10 (IL-10) were
transferred intravenously to recipient mice. One week later, 2104 cells of the ApoB100-specific T hybridoma 48.5 were seeded together
with 1104 DCs and 20 g/mL ApoB100 in 96-well plates. CD4 T cells purified from spleens of DC-treated mice were coincubated at dif-
ferent ratios with the T hybridoma effector cells. Antigen-specific T-cell activation was measured 24 hours later by interleukin-2 (IL-2) secre-
tion in the supernatant. Black bars indicate T effector cells and DCs only. Ratios are shown as suppressor-to-effector ratio. *P0.05 vs effec-
tors only (n4). B, DCs pulsed with or without ApoB100 and IL-10 were transferred intravenously to recipient mice that were immunized 1
week later with a subcutaneous injection of 100 g of ApoB100 to boost the cellular immune response to this protein. After another week,
the in vitro recall cytokine response against ApoB100 (40 g/mL) was measured in cultures of 5105 splenocytes from the treated mice. Cy-
tokine secretion in cell supernatants was analyzed after 48 hours with enzyme-linked immunosorbent assay. IFN indicates interferon-; IL-5,
interleukin-5; and TNF, tumor necrosis factor-. *P0.05 (n5 mice per group).
Table. Body Weight, Plasma Cholesterol, and Triglyceride Levels
Group
Cholesterol,
mg/dL
Triglycerides,
mg/dL Weight, g
DC 1008241 659210 27.32.9
DCApoB100 1050266 863675 294.8
DCApoB100IL-10 1231142 712165 28.11.6
DCIL-10 1244250 718223 28.22.5
No DC 1008262 683253 31.32.3
P NS NS NS
DC indicates dendritic cell; ApoB100, apolipoprotein B100; IL-10,
interleukin-10; and NS, not significant.
Values are expressed as meanSD. n7–9 mice per group.
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decrease (70%) in surface lesion area of the descending
thoracic aorta was observed in mice that received ApoB100-
loaded tolerogenic DCs compared with all other groups that
received DCs (55% reduction compared with untreated mice;
Figure 3).
Immunohistochemical analysis of cryosections from the
aortic root showed significantly reduced infiltration of CD4
T cells in atherosclerotic lesions of mice that received
ApoB100-loaded tolerogenic DCs compared with mice that
received DCs pulsed with ApoB100 alone (Figure 4A).
Lesions of mice injected with ApoB100-loaded tolerogenic
DCs displayed significantly increased amounts of collagen
fibers compared with mice that received unloaded tolerogenic
DCs (Figure 4B). No significant differences between treat-
ment groups were registered by immunohistochemical anal-
ysis of CD8, CD11c, vascular cell adhesion molecule-1, and
I-Ab (online-only Data Supplement Figure IV). Very few
FoxP3 cells were detected in lesions of any of the groups
(data not shown). Aortic FoxP3 mRNA levels did not differ
between groups (online-only Data Supplement Figure V).
Body weight, plasma cholesterol, and triglyceride levels did
not differ between groups (Table).
ApoB100-Loaded Tolerogenic DCs Induce
Antigen-Specific CD4 Treg Cells That Suppress
T-Cell Effector Responses to ApoB100
To investigate the functional activity of Treg cells in the
huB100tgLdlr/ mice treated with tolerogenic DCs, we
purified CD4 T cells from spleens of treated mice and tested
whether they could suppress activation of a T-cell hybridoma
that recognizes ApoB100 in an I-Ab–restricted manner.
CD4 T cells from mice injected with tolerogenic ApoB100-
pulsed DCs significantly suppressed activation of the
ApoB100-specific T cells (Figure 5A). None of the CD4
T-cell populations from mice injected with DCs and treated
with antigen or cytokine alone could suppress these
ApoB100-specific T cells (Figure 5A).
ApoB100-Loaded Tolerogenic DCs Downregulate
Proinflammatory T-Cell Responses in an
Antigen-Dependent Manner and Mobilize
Antiinflammatory Activity In Vivo
Splenocytes from huB100tgLdlr/ mice proliferate in
response to human ApoB100 and display a Th1 cytokine
profile.5 We transferred tolerogenic DCs to test whether this
response can be suppressed in vivo. When recipients were
injected subcutaneously with 100 g of ApoB100 1 week
after injection of ApoB100-pulsed DCs, a vivid recall re-
sponse was registered to the protein, with splenocytes secret-
ing increased amounts of IFN-, TNF-, and IL-6 in response
to ApoB100 (Figure 5B). However, spleens of mice injected
with ApoB100-loaded tolerogenic DCs displayed signifi-
cantly decreased production of IFN-, TNF-, and IL-6, as
well as IL-5 (Figure 5B). This indicates that the tolerogenic
treatment reduced antigen-specific responses in immunized
mice.
mRNA levels for FoxP3, IL-10, and transforming growth
factor-1 were increased and IL-12 was decreased in spleens
of mice that received ApoB100-loaded tolerogenic DCs
(Figure 6). Transcripts for ICOS ligand, PD-1, and PD-L1
were increased after treatment with IL-10–pulsed DCs irre-
spective of whether they were loaded with antigen (online-
only Data Supplement Figure VI). Lymph nodes of mice
treated with tolerogenic DCs showed significantly lower
levels of IL-12 and IL-5 and increased levels of ICOS ligand
compared with mice that received DCs pulsed with ApoB100
alone (online-only Data Supplement Figure VI). These data
show that tolerogenic DCs induce a regulatory and antiin-
flammatory machinery in the lymphoid organs of treated
mice.
The Atheroprotective Effect of Tolerogenic DCs
Is Associated With Decreased Cellular But Not
Humoral Immunity to ApoB100
Hypercholesterolemic mice injected with ApoB100-loaded
tolerogenic DCs displayed significantly suppressed prolifer-
ative spleen T-cell responses to ApoB100 at 40 g/mL
(Figure 7A). Plasma levels of IFN- were also decreased
significantly in these mice compared with mice that received
ApoB100-loaded DCs (Figure 7B). IgG antibodies to
ApoB100 were increased significantly in the 2 groups of mice
that received DCs pulsed with ApoB100, irrespective of
whether they were treated with IL-10 to become tolerogenic
(Figure 7C). A similar trend was seen for IgG antibodies to
oxidized LDL (data not shown). No significant differences
were seen for IgM titers against ApoB100 in plasma of
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injected mice (Figure 7D). Therefore, the atheroprotective
effect of ApoB100-loaded tolerogenic DCs is associated with
inhibition of effector T-cell responses but not antibody
production.
Discussion
The significant role of adaptive immunity in atherosclerosis is
well established and makes it likely that antigen-presenting
DCs are of importance for disease development. This was
recently supported by studies that showed that transfer of
LDL-loaded DCs into hypercholesterolemic mice accelerated
atherosclerosis,31 and that an extended lifespan of DCs
affected plaque inflammation and cholesterol metabolism.37
One may surmise that manipulation of DC activity could be
used to reduce the autoimmune response to LDL components
and ameliorate atherosclerosis.
We now show that DCs can be made tolerogenic to LDL
autoimmunity by treating them with IL-10 while loading
them with ApoB100. Such ApoB100-loaded tolerogenic DCs
inhibited the proliferative and proinflammatory T-cell re-
sponse to ApoB100 and promoted the development of regu-
latory T cells. When injected into atherosclerosis-prone
huB100tgLdlr/ mice, they induced antiinflammatory ac-
tivity, reduced immune cell infiltration into lesions, and
mediated a significant reduction of atherosclerotic lesion size
compared with immunogenic ApoB100-loaded DCs or vehi-
cle controls.
The atheroprotective effect of ApoB100-loaded tolero-
genic DCs was paralleled by reduced plasma levels of IFN-
and reduced CD4 T-cell infiltration into lesions but affected
neither entry of CD11c DCs, expression of major histocom-
patibility complex class II (I-A) or vascular cell adhesion
molecule-1 in lesions, nor plasma lipid levels. This suggests
that activation and recruitment to lesions of effector T cells is
of major importance for the atheroprotective effect of these
tolerogenic DCs. Because FoxP3 Treg and the coinhibitory
molecule PD-1 were increased in T-cell populations exposed
to tolerogenic DCs and a significant inhibition of helper
T-cell immunity was seen in mice injected with such DCs, the
present data point to suppression of cell-mediated immune
responses as a likely pathway. This is in line with previous
studies showing inhibitory effects on effector T-cell immu-
nity when Treg function was stimulated by IL-10–treated
tolerogenic DCs.21,26,38 It has been suggested that the effects
of such tolerogenic DCs are mediated by downregulation of
costimulatory molecules, major histocompatibility complex
class II, and IL-12.21 We did not see any such difference in
surface-marker expression; however, IL-12 expression was
repressed in tolerogenic DCs and in lymphoid organs of mice
injected with these DCs. IL-12 is one of the major determi-
nants for differentiation of naı¨ve T cells into effector Th1
cells, with ensuing production of IFN-.39 This further
supports the present data that the effect of tolerogenic DCs on
atherosclerosis is mediated by suppression of effector T-cell
immunity.
The notion that antigen-specific tolerogenic DCs operate
through cell-mediated immunity when reducing atherosclero-
sis is also supported by the reduced T-cell proliferation to
apoB100 in treated mice in the present study. In contrast,
B-cell responses to ApoB100 were not affected significantly.
This suggests that humoral immunity is less important than
cellular immunity for the atheroprotective effect of tolero-
genic DCs.
Several lines of evidence support a role for antigen
specificity in atheroprotective immunity. Only tolerogenic
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DCs loaded with apoB100 antigen had a protective effect; the
fact that just a single injection of such DCs was sufficient to
achieve protection 10 weeks later points to a role for
immunologic memory. Of note, DCs prepared in this way
present not only the loaded antigen (in this case, apoB100)
but also BSA, which is present in the medium needed for DC
differentiation.40 Presentation of BSA did not affect disease,
because lesions of mice that received tolerogenic DCs with-
out apoB100 did not differ from those of control mice that did
not receive any DCs. Instead, atheroprotection was dependent
on presentation of ApoB100 by tolerogenic DCs.
We and others have previously shown that repeated immu-
nization with antigen-loaded immunogenic DCs increases
atherosclerosis.31,41 This effect was observed both when DCs
were loaded with oxidized LDL25 and when they were loaded
with an artificial antigen expressed transgenically in the
artery wall.41 In contrast, it was reported recently that
immunogenic DCs loaded with oxidized LDL reduced lesions
induced when a collar was surgically attached to the carotid
artery of hypercholesterolemic mice, whereas aortic lesions
were unchanged.42
The present study may shed light on these seemingly contra-
dictory studies. When ApoB100-pulsed immunogenic DCs were
administered, a modest, nonsignificant increase in lesion size
was observed. Tolerogenic modulation of DCs by IL-10 treat-
ment led to a significant reduction of lesions under otherwise
similar conditions. Therefore, the local concentration of IL-10
and other mediators that influence DC phenotype could conceiv-
ably determine the outcome of DC transfer experiments. Be-
cause IL-10 expression increases with increasing plasma cho-
lesterol levels,43 the choice of hypercholesterolemic
atherosclerosis model may also affect the balance between
conventional and tolerogenic DCs. When these findings are
translated into clinical use for humans, the immunologic prop-
erties of donor and recipient will also be of major importance,
because only human leukocyte antigen–matched tolerogenic
DCs are likely to confer atheroprotection.
Conclusions
We present here a novel treatment regimen for atherosclerotic
disease. Using a tolerogenic DC therapy that targets immune
reactions to the ApoB100 protein present in LDL, it was
possible to attenuate systemic inflammation and reduce the
atherosclerotic plaque burden by 70%. Because both LDL
and markers of inflammation are major risk factors for
coronary and cerebrovascular disease, and because current
treatment benefits only a limited proportion of all those
considered at risk, the present findings should encourage
development of DC therapy as an additional approach to
cardiovascular prevention and therapy.
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CLINICAL PERSPECTIVE
In recent years, the perception of atherosclerotic cardiovascular disease has changed from that of a vascular lipid disorder
to a chronic inflammatory condition elicited by lipoprotein retention in the vessel wall. Components of the accumulating
low-density lipoprotein particles are immunogenic and can activate T cells and macrophages that promote inflammation,
lesion growth, and plaque vulnerability. We devised a cell-therapy strategy to dampen inflammation and reduce
atherosclerosis by injecting tolerogenic dendritic cells into hypercholesterolemic mice. Before transfer, dendritic cells were
loaded with apolipoprotein B100, the protein part of low-density lipoprotein, and subsequently exposed to the
antiinflammatory cytokine interleukin-10. Such dendritic cells suppressed the activity of apolipoprotein B100–reactive T
cells. A single injection of tolerogenic dendritic cells loaded with apolipoprotein B100 significantly reduced atherosclerosis
and increased plaque-stabilizing collagen in hypercholesterolemic mice. Because similar immune responses occur in
human atherosclerosis, tolerogenic dendritic cell therapy may represent a new strategy for reduction and stabilization of
atherosclerotic lesions in humans.
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SUPPLEMENTAL MATERIAL 
 
 
Supplemental Methods 
  
 
 
Preparation of ApoB100 
 
LDL (d = 1.019 – 1.063 g/mL) was isolated by ultracentrifugation from pooled plasma of 
healthy donors, as described
1
. After isolation, LDL was dialyzed extensively against 
PBS. One millimolar EDTA was added to an aliquot of LDL to generate unmodified 
LDL. ApoB100 was isolated by using a modification of previously described methods
2-3
. 
Briefly, 0.4 ml methanol, 0.1 ml chloroform, and 0.3 ml water were added to 0.1 ml of 
LDL (1mg/mL); the suspension was then vortexed and centrifuged at 9000 x g for 1 min. 
The upper phase was removed and 0.3 ml of methanol added to the lower phase and 
interphase with precipitated protein, which was mixed again and centrifuged at 9000 x g 
for 2 min to pellet the protein.  
To obtain soluble, purified ApoB100, the protein pellet was resuspended in a minimum 
volume of 10% SDS (Bio-Rad Laboratories, Hercules, CA, USA) until it solubilized. 
These preparations first were filtered on a PD-10 column (GE Healthcare, previously 
Amersham Biosciences, Uppsala, Sweden) to remove excess SDS. They were then 
purified on a Superdex-200 size-exclusion column (0.5 mL/min, in Tris-HCl, pH 7.4). 
The first peak that contained ApoB100 was collected. ApoB100 preparations were 
greater than 90% pure, as evaluated by gel-filtration HPLC (GE Healthcare, Uppsala, 
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Sweden). Protein concentration was determined by the Bradford assay (Bio-Rad 
Laboratories, Hercules, CA, USA).  
 
In vitro cell culture assay 
Splenocytes from treated mice were isolated and resuspended in 96-well plates. 5 x 10
5
 
splenocytes were incubated with or without ApoB100 antigen in 200 μL of DMEM 
supplemented with 2.5% mouse serum, 50U/ml penicillin, 50µg/ml streptomycin, 2mM 
L-glutamine, 1mM sodium pyruvate for 72 hours at 37°C in a humid 5% CO2 
atmosphere. One Ci 3H-thymidine (Sigma-Aldrich, St.Louis, MO, USA) was added 
after 60 h, and DNA replication measured with a scintillation counter (Wallac, Turku, 
Finland). Results are expressed as stimulation index = ((s – c)/c), where s is the cpm of 
the sample with antigen and c is the cpm of the sample without antigen. Cytokines 
secreted in the cell culture supernatants after 72 hours were measured with a mouse 
IFNELISA kit (Mabtech, Sweden) and by using the cytometric bead array flex set kit 
(BD Biosciences, CA, USA) for IL-21, MCP-1, IL-10, IL-6, TNFα, IL-12 and IL-5. In 
some experiments, 4x10
5 
antigen-pulsed and cytokine-treated DC were incubated with 
1x10
5
 cells of the T cell hybridoma 48.5, which can recognize human ApoB100 in an I-
A
b
 restricted manner and release IL-2 upon activation. This cytokine was measured with 
mouse IL-2 ELISA kit (R&D systems, USA).  
 
Tissue processing, immunohistochemistry and lesion analysis 
Blood from sacrificed mice was collected by cardiac puncture and vascular perfusion 
performed with sterile RNase-free PBS. Abdominal aorta, one third of the spleen, and 
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draining lymph nodes were dissected and snap-frozen for later RNA isolation. Hearts and 
aortic root were dissected and preserved for immunohistochemistry. Lesion analysis was 
performed as described
4
. Briefly, hearts were serially sectioned from the proximal 1 mm 
of the aortic root on a cryostat. Primary antibodies to CD4, CD8, CD11c, I-Ab and 
VCAM-1 (all rat anti-mouse from BD Biosciences, Franklin Lakes, NJ, USA) were 
applied to acetone-fixed cryosections followed by detection with the ABC alkaline 
phosphatase kit (Vector Laboratories, Burlingame, CA,USA). En face lipid accumulation 
was determined in the aortic arch from immunized mice using Sudan IV staining. Briefly, 
dissected arches were fixed in 4% neutral buffered formalin. Samples were then cut 
longitudinally, splayed, pinned and subjected to Sudan IV staining (red color). Images 
were captured using a Leica DC480 camera connected to a Leica MZ6 stereo microscope 
(Leica, IL, USA). The additive area of all the plaques in a given aortic arch was 
calculated as a percent of the total surface area of the arch (not including branching 
vessels). Quantitation of plaques was performed using Image J software (NIH, Bethesda, 
USA). Immunohistochemical data was obtained using Qwin computerized analysis 
(Leica, IL, USA) of stained sections. 
 
Flow cytometry and Intracellular Cytokine Staining 
 
Flow cytometry was performed on a CyAn
TM
 (Dako, Glostrup, Denmark); data were 
analyzed using Summit v4.3 software (Dako). Primary labeled antibodies were from BD 
Biosciences (anti-CD4, -CD11c, -Flt3, -CD80, -CD86, -I-A
b
, -PD-L1, -PD-L2, -PD-1, -
CTLA-4, -CD28, -ICOS, -IFNγ, and anti-IL-10) or from eBioscience (anti-FoxP3). To 
characterize the cytokine expression profiles of CD4+ T cells from mouse spleen 
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incubated with treated DC, cell suspensions were prepared as described before and CD4+ 
T cells (> 95% purity) were isolated by negative selection over a magnetic column using 
MACS microbeads (CD4+ negative selection kit, Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany) according to the manufacturer’s protocol. 1x104 CD4+ T cells were 
incubated for 96h with 4x10
4
 DC treated with or without IL-10 in the presence of anti-
CD3 (2µg/ml) and were restimulated for the last 4h of culture at 37 °C in 7.5% CO2 with 
PMA (phorbol 12-myristate 13-acetate; 50 ng/ml), ionomycin (1 ug/ml; Sigma) and 
GolgiPlug (1ul per 1 ml; BD Bioscience). All cells were incubated with FcγR block (BD 
Bioscience) followed by surface staining for CD4) and intracellular staining for IFNγ, IL-
10 (BD Bioscience) or FoxP3 (eBioscience) according to the manufacturer´s instructions. 
In some experiments cell proliferation was measured by staining with carboxyfluorescein 
succinylesther (CFSE;Invitrogen, Carlsbad, CA, USA ).  
 
RNA isolation, cDNA synthesis, and real-time PCR 
RNA was isolated from the indicated tissues or cells using the RNeasy kit (Qiagen, 
Hilden, Germany).Total RNA was analysed on a BioAnalyzer (Agilent Technologies, 
Waldbronn, Germany). Reverse transcription was performed with Superscript-II and 
random hexamers (both from Invitrogen, Carlsbad, USA) and amplified by real time-
PCR using Assay-on-demand primers and probes for FoxP3, IL-5, IL-10, IL-12, TGFb1, 
ICOS-L, PD-1, PD-L1 and TATAbox (Applied Biosystems, Foster City, CA, USA) in an 
ABI 7700 Sequence Detector (Applied Biosystems, Foster City, CA, USA). Data was 
analyzed on the basis of the relative expression method with the formula 2-ΔΔCT , where 
ΔΔCT = ΔCT (sample) – ΔCT (calibrator = average CT values of all samples within each 
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group), and ΔCT is the CT of the housekeeping gene (TATAbox) subtracted from the CT 
of the target gene.  
 
Plasma analyses 
The titers of specific antibodies to ApoB100 were measured by ELISA. Briefly, 50 µL of 
ApoB100 (10µg/mL in PBS pH 7.4) was added to 96-well ELISA plates and incubated 
overnight at 4°C. Coated plates were washed with PBS and blocked with 1% gelatin 
(Gibco Invitrogen, Carlsbad, CA, USA) in PBS for 1 hr at room temperature. Next, plates 
were washed and incubated for an additional two hours with mouse plasma, diluted in 
Tris-buffered saline (TBS)/gelatin 0.1%. After washing, total IgG or IgM levels were 
measured using enzyme-conjugated anti-mouse antibodies (BD Biosciences, Franklin 
Lakes, NJ, USA). Colorimetric reactions were developed using TMB (BD Biosciences, 
Franklin Lakes, NJ, USA) and absorbance measured using a microplate reader 
(VersaMax, Molecular Devices, Sunnyvale, CA, USA). Plasma cholesterol and 
triglycerides were measured using enzymatic colorimetric kits (Randox Lab. Ltd. 
Crumin, UK) according to the manufacturer’s protocol. 
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Supplemental Tables  
 
Supplemental Table I.  Mean fluorescent intensity (MFI) of FoxP3 expressed in 
CD4+ T cells after DC co-culture. Flow cytometry analysis of immunostained cells. 
 
                   Group (MFI ± CV) 
Cell surface marker DC DC + IL-10  
FoxP3 460 ± 147 707 ± 93  
 
 
 
 
 
 
 
Supplemental Table II.  Number of dividing CD4+ T cells after DC co-culture. 
Flow cytometry analysis of CFSE stained cells (mean ± SEM). 
 
                                  Group (number of cells) 
Cell divisions DC DC + IL-10 
0 – 1   2,114 ± 904  11,026 ± 7,231 
2 – 3 31,559 ± 21,540 93,389 ± 19,618 
>3 73,618 ± 26,332 21,100 ± 19,618 
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Supplemental Figures  
Supplemental Figure I 
Surface marker analysis of tolerogenic dendritic cells (DC). DC were differentiated from 
mouse bone marrow in the presence of GM-CSF and IL-4 according to a method adapted 
from Son et al. CD11c+ dendritic cells were purified using magnetic cell sorting and 
matured with LPS. 2x10
5 
cells incubated in the presence or absence of IL-10 for 24h were 
analysed for cell specific surface markers CD11c, Flt3 and I-A
b
 as well as co-stimulatory 
markers CD80/CD86 and co-inhibitory PD-L1/PD-L2. Dotted line shows negative 
control, grey profile indicates cells without IL-10 and black line shows cells with IL-10. 
Histograms are representative of several experiments. 
 
Supplemental Figure II 
Effect of tolerogenic DC on surface marker expression of activated CD4+ T cells. 1x10
4
 
CD11c+ dendritic cells treated with or without IL-10 were co-incubated for 96h with 
4x10
4
 CD4+ T cells purified from mouse spleen and activated with anti-CD3.Staining of 
co-stimulatory surface markers CD28 and ICOS, and co-inhibitory markers CTLA-4 and 
PD-1, on CD4+ T cells 96h after co-incubation with dendritic cells. Grey profile indicates 
co-cultured dendritic cells matured without IL-10 and black line shows IL-10-treated 
dendritic cells. 
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Supplemental Figure III 
5x10
4
 cells of the T cell hybridoma 48.5, which specifically recognizes ApoB100, were 
co-incubated with 2x10
5
 DC in the presence of ApoB100 and different concentrations of 
an antibody against I-Ab. The DC originated from donor mice expressing I-Ab. T cell 
effector function was measured 24h later by IL-2 secretion in the supernatant. 
 
Supplemental Figure IV 
No effect of tolerogenic DC on infiltration of CD8+ T cells and DC, or on expression of 
VCAM-1 and I-A
b
 in aortic root lesions of huB100
tg
xLdlr-/- mice. Mice received one 
injection I.V. with DC loaded with or without ApoB100 and/or IL-10 and fed Western 
diet for 10 weeks. Graphs show the number of cells per mm
2
 lesion area or the percent 
stained lesion area. (n=5-7 mice per group). 
 
Supplemental Figure V 
No effect of DC transfer on FoxP3 mRNA in aortas of huB100
tg
xLdlr-/- mice. Mice 
received one injection I.V. with DC loaded with or without ApoB100 and/or IL-10 and 
fed Western diet for 10 weeks. FoxP3 mRNA was analyzed by real-time reverse-
transcription PCR. Bar graphs represent mean ± SEM of target mRNA relative to TATA 
box protein mRNA. 
 
Supplemental Figure VI 
In vivo transfer of IL-10-treated ApoB100-pulsed DC mobilizes anti-inflammatory 
activity in lymphoid organs. mRNA transcript levels was evaluated with real-time PCR 
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from (A) spleen and (B) inguinal lymph nodes of recipient mice that had been injected 
I.V with DC pulsed and treated with or without ApoB100 and IL-10, and primed one 
week later with ApoB100. Bar graphs represent the mean ± SEM expression of target 
gene relative to TATAbox expression. * = p<0.05, as compared to DC or DC + ApoB100 
(n=5 mice per group). 
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Supplemental Figure I 
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Supplemental Figure II 
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Supplemental Figure III 
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Supplemental Figure IV 
 
 
 
 
D
C
D
C
+
A
po
B
10
0
D
C
+
A
po
B
10
0
+
IL
-1
0
D
C
+
IL
-1
0
0
50
100
150
200
250
C
D
8
+
ce
ll
s
p
er
m
m
2
le
si
o
n
ar
ea
D
C
D
C
+
A
po
B
10
0
D
C
+
A
po
B
10
0
+
IL
-1
0
D
C
+
IL
-1
0
0
2
4
6
%
IA
b
st
ai
n
in
g
in
ao
rt
ic
ro
o
t
D
C
D
C
+
A
po
B
10
0
D
C
+
A
po
B
10
0
+
IL
-1
0
D
C
+
IL
-1
0
0
10
20
30
%
V
C
A
M
-1
st
ai
n
in
g
in
ao
rt
ic
ro
o
t
D
C
D
C
+
A
po
B
10
0
D
C
+
A
po
B
10
0
+
IL
-1
0
D
C
+
IL
-1
0
0
5
10
15
20
%
C
D
1
1
c
st
ai
n
in
g
in
th
e
ao
rt
ic
ro
o
t
 at SWETS BLACKWELL INC on May 25, 2012http://circ.ahajournals.org/Downloaded from 
14 
 
Supplemental Figure V 
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Supplemental Figure VI 
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